Scholarlink

<p>Autosomal recessive polycystic kidney disease (ARPKD) is the prototype of the hepato-renal fibrocystic diseases, a subset of the broader ciliopathy disorders. As a severe form of PKD, ARPKD typically manifests in utero with 21% perinatal mortality and progressive loss of kidney function in most post-natal survivors. Congenital hepatic fibrosis is an invariant feature of ARPKD. <i>PKHD1</i>-encoded fibrocystin/polyductin (FPC) is a large 4074 amino acid glycoprotein that likely functions as a receptor molecule and appears to play a key role in maintaining differentiated renal tubular epithelium. The molecular mechanisms by which defects in FPC contribute to ARPKD pathogenesis are just beginning to be elucidated. FPC is a novel protein that likely evolved as vertebrates transitioned from aquatic to semi-terrestrial ecosystems. Full-length human FPC shares a phylogenetically conserved, multi-motif N-terminal region with its ancestral homolog, <i>PKHD1L1</i>, and contains a single-pass transmembrane domain and a novel C-terminal tail that harbors a ciliary targeting motif as well as mitochondrial and nuclear localization sequences. This review synthesizes the full range of recent experimental data about <i>PKHD1</i>/FPC to provide a current functional perspective about this complex protein. We also discuss the clinical relevance of these emerging functional insights for both kidney health and ARPKD pathogenesis.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fibrocystin/polyductin (FPC): new functional insights into ARPKD pathogenesis revealed by informatics, comparative genomics, and model systems

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月28日

查看全文
  • Ashima Gulati,
  • Ljubica Caldovic,
  • Lisa M. Guay-Woodford

摘要

Autosomal recessive polycystic kidney disease (ARPKD) is the prototype of the hepato-renal fibrocystic diseases, a subset of the broader ciliopathy disorders. As a severe form of PKD, ARPKD typically manifests in utero with 21% perinatal mortality and progressive loss of kidney function in most post-natal survivors. Congenital hepatic fibrosis is an invariant feature of ARPKD. PKHD1-encoded fibrocystin/polyductin (FPC) is a large 4074 amino acid glycoprotein that likely functions as a receptor molecule and appears to play a key role in maintaining differentiated renal tubular epithelium. The molecular mechanisms by which defects in FPC contribute to ARPKD pathogenesis are just beginning to be elucidated. FPC is a novel protein that likely evolved as vertebrates transitioned from aquatic to semi-terrestrial ecosystems. Full-length human FPC shares a phylogenetically conserved, multi-motif N-terminal region with its ancestral homolog, PKHD1L1, and contains a single-pass transmembrane domain and a novel C-terminal tail that harbors a ciliary targeting motif as well as mitochondrial and nuclear localization sequences. This review synthesizes the full range of recent experimental data about PKHD1/FPC to provide a current functional perspective about this complex protein. We also discuss the clinical relevance of these emerging functional insights for both kidney health and ARPKD pathogenesis.

Graphical Abstract